Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521994

SCHEMBL1521994

SCHEMBL1521994

CCN1C(=O)N(c2cc(NC(=O)Nc3cc(C(C)C)no3)c(F)cc2Cl)Cc2cnc(NC)cc21

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.40
▸ BRAF P15056 4/20 0.39
▸ KRAS P01116 3/20 0.39
▸ RAF1 P04049 3/20 0.39
▸ KDR P35968 3/20 0.39
▸ MAP2K2 P36507 3/20 0.39
▸ MAP2K1 Q02750 3/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ FGFR4 P22455 8/20 0.36
▸ FGFR1 P11362 7/20 0.36
▸ NEK7 Q8TDX7 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ KIT P10721 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ FGFR2 P21802 1/20 0.32
▸ FGFR3 P22607 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521672 0.93 BRAF (0.40) MAPK14BRAFKRASRAF1KDR
SCHEMBL1521753 0.89 BRAF (0.51) MAPK14BRAFKRASRAF1KDR
SCHEMBL1521624 0.88 BRAF (0.44) MAPK14BRAFKRASRAF1KDR
SCHEMBL1521861 0.87 MAPK14 (0.39) MAPK14BRAFKRASRAF1KDR
SCHEMBL1521533 0.83 FGFR4 (0.40) SMN1; SMN2FGFR4FGFR1KITPDGFRA
SCHEMBL1522010 0.82 BRAF (0.52) MAPK14BRAFKRASRAF1KDR
SCHEMBL1521431 0.82 BRAF (0.52) MAPK14BRAFKRASRAF1KDR
SCHEMBL1521602 0.81 TRPV1 (0.40) FGFR4FGFR1ALDH1A1LMNAKIT
SCHEMBL1521751 0.80 TNK2 (0.42) MAPK14BRAFKRASRAF1KDR
SCHEMBL1521499 0.79 BRAF (0.47) MAPK14BRAFKRASRAF1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 MAPK14 240/4885BRAF 1/4885KRAS 30/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPK14 240/4885BRAF 1/4885KRAS 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.